MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 414579 | Name: ONL-1204

Description:

WARNING: This product is for research use only, not for human or veterinary use.

ONL-1204 is a small molecule, CD95 antigen inhibitor (Fas inhibitor) being developed by ONL Therapeutics for the treatment of retinal detachment.

Chemical Structure

ONL-1204
ONL-1204
CAS#2040964-58-5

Theoretical Analysis

MedKoo Cat#: 414579

Name: ONL-1204

CAS#: 2040964-58-5

Chemical Formula: C71H100N18O16

Exact Mass: 1460.7565

Molecular Weight: 1461.69

Elemental Analysis: C, 58.34; H, 6.90; N, 17.25; O, 17.51

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
ONL-1204; ONL1204; ONL 1204
IUPAC/Chemical Name
(S)-2-((2S,5S,11S,14S,17S,20S,23S)-20-((1H-imidazol-4-yl)methyl)-23-amino-17-((S)-sec-butyl)-14-(4-hydroxybenzyl)-24-(1H-imidazol-4-yl)-11-isobutyl-2-isopropyl-5-methyl-4,7,10,13,16,19,22-heptaoxo-3,6,9,12,15,18,21-heptaazatetracosanamido)-N1-((S)-1-(((2S,3S)-1-(((S)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl)amino)-3-methyl-1-oxopentan-2-yl)amino)-3-(4-hydroxyphenyl)-1-oxopropan-2-yl)succinamide
InChi Key
MDQMJABKOUZYGG-QZJYLVOGSA-N
InChi Code
InChI=1S/C71H100N18O16/c1-10-38(7)59(70(104)81-50(61(74)95)25-41-12-18-46(90)19-13-41)88-67(101)53(27-43-16-22-48(92)23-17-43)84-66(100)55(30-56(73)93)86-69(103)58(37(5)6)87-62(96)40(9)80-57(94)33-77-64(98)51(24-36(3)4)83-65(99)52(26-42-14-20-47(91)21-15-42)85-71(105)60(39(8)11-2)89-68(102)54(29-45-32-76-35-79-45)82-63(97)49(72)28-44-31-75-34-78-44/h12-23,31-32,34-40,49-55,58-60,90-92H,10-11,24-30,33,72H2,1-9H3,(H2,73,93)(H2,74,95)(H,75,78)(H,76,79)(H,77,98)(H,80,94)(H,81,104)(H,82,97)(H,83,99)(H,84,100)(H,85,105)(H,86,103)(H,87,96)(H,88,101)(H,89,102)/t38-,39-,40-,49-,50-,51-,52-,53-,54-,55-,58-,59-,60-/m0/s1
SMILES Code
CC[C@@H]([C@@H](C(N[C@H](C(N)=O)Cc1ccc(O)cc1)=O)NC([C@@H](NC([C@@H](NC([C@H](C(C)C)NC([C@@H](NC(CNC([C@@H](NC([C@@H](NC([C@H]([C@H](CC)C)NC([C@@H](NC([C@H](Cc2nc[nH]c2)N)=O)Cc3nc[nH]c3)=O)=O)Cc4ccc(O)cc4)=O)CC(C)C)=O)=O)C)=O)=O)CC(N)=O)=O)Cc5ccc(O)cc5)=O)C
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 1,461.69 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Krishnan A, Kocab AJ, Zacks DN, Marshak-Rothstein A, Gregory-Ksander M. A small peptide antagonist of the Fas receptor inhibits neuroinflammation and prevents axon degeneration and retinal ganglion cell death in an inducible mouse model of glaucoma. J Neuroinflammation. 2019 Sep 30;16(1):184. doi: 10.1186/s12974-019-1576-3. PMID: 31570110; PMCID: PMC6767653. 2: Rolle T, Ponzetto A, Malinverni L. The Role of Neuroinflammation in Glaucoma: An Update on Molecular Mechanisms and New Therapeutic Options. Front Neurol. 2021 Feb 4;11:612422. doi: 10.3389/fneur.2020.612422. PMID: 33613418; PMCID: PMC7890114.